Views ML
Founded 2022 · 16 employees on LinkedIn · 7 known investors
ViewsML applies AI to support the development and delivery of precision medicines, including virtual IHC technology for pathology. It operates in the AI-driven healthcare and diagnostics space.
Also known as Views ML · ViewsML
Founders & leadership
Investors · 7
Also in the syndicate · 2
Company profile
researched Aug 2026ViewsML applies deep learning to the virtualization of immunohistochemistry (IHC), generating virtual biomarker staining results from tissue images instead of physical staining. The company states that its approach delivers results in seconds at a fraction of the cost of traditional IHC, can be trained to any biomarker across disease types and species, and supports multiplexing for broader biomarker characterization while preserving scarce tissue samples.
The platform is aimed at several segments of the drug development and diagnostics chain: preclinical research (discovery, toxicity and safety studies), translational research (spatial biology insights on rare tissues via virtual multiplexing), clinical research (patient selection and trial enrollment efficiency), virtual diagnostic assays (patient stratification, triaging and companion diagnostics), and contract research organizations (faster project turnaround and richer data sets). Management has described the objective as building the world's first AI biomarker library capable of generating per-cell biomarker insights without laboratory staining, reducing analysis timelines from days or weeks to minutes.
Business model
ViewsML develops and commercializes a software platform that produces virtual biomarker staining results from tissue images, positioning itself as a computational layer for diagnostics that is designed to fit into existing preclinical and clinical laboratory workflows rather than replace them with new physical instrumentation.
Latest developments
In April 2026, ViewsML announced a $4.9 million seed financing led by Wittington Ventures, with new investor Mayo Clinic and repeat investor RiSC Capital, earmarked for accelerating commercialization of its virtual biomarker staining platform and building a virtual biomarker library. In July 2026, the company was named to Life Sciences BC's 2026 Companies to Watch list.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
ViewsML positions itself in AI-driven diagnostics and precision medicine, targeting biomarker detection workflows where results from diagnostic laboratories can take weeks and interpretation can vary by up to 30% between pathologists. The company cites that roughly 20% of the world's population will be diagnosed with cancer, about 35% of those will be treated with precision medicine, and 80% of precision medicine relies on biomarker identification.
The company frames its virtual staining approach against physical IHC and immunofluorescence, citing elimination of the time and cost of laboratory staining, consistent and reproducible immunostaining outputs, preservation of limited tissue, multiplexing capability, and trainability to any biomarker, therapeutic area or species. It also positions the product as integrating into existing preclinical and clinical workflows.
Technology
The core technology uses deep learning to produce virtual IHC results from tissue images, eliminating physical staining. Stated capabilities include per-cell biomarker insights, virtual multiplexing for greater biomarker characterization, reproducible immunostaining outputs, and model training to any biomarker across any disease type and species.
Go-to-market
Pharmaceutical and biotechnology researchers in preclinical, translational and clinical development; contract research organizations; and clinical laboratories and pathologists involved in patient stratification, triaging and companion diagnostics.
Geography
The company is linked to Canada's British Columbia technology ecosystem through its association with SFU VentureLabs and its inclusion on Life Sciences BC's 2026 Companies to Watch list.
History
ViewsML operates as a Perago company and is associated with SFU VentureLabs. In April 2026 it announced a $4.9 million seed round led by Wittington Ventures with participation from Mayo Clinic and returning investor RiSC Capital, capital intended to accelerate commercialization and the build-out of a virtual biomarker library. In July 2026 it was named to Life Sciences BC's 2026 Companies to Watch list.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsViewsML was included on Life Sciences BC's 2026 Companies to Watch list.
ViewsML, a Perago company, announced it had secured $4.9 million in seed funding to accelerate commercialization of its AI-driven virtual biomarker staining platform, with participation from Mayo Clinic (new) and RiSC Capital (returning).
$4.9M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- Views MLviewsml.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Views ML do?
- ViewsML uses deep learning to replace physical immunohistochemistry with virtual biomarker staining for research and diagnostics.
- Who are Views ML's investors?
- Views ML's investors include Debiopharm Innovation Fund, SFU VentureLabs, Swan Venture Fund, Wittington Ventures, WUTIF Capital.